Somnomed Limited · ASX:SOM
Somnomed — Shareholder Meeting (November 2025)
12 slides from Somnomed's shareholder meeting presentation, Nov 27, 2025
Slide 1: Annual General Meeting 2025
Annual General Meeting 2025 27 November 2025 Treatment focused. Technology driven.
Slide 2: Disclaimer
Disclaimer This document has been prepared as a summary only and does not contain all information about SomnoMed Limited’s (the Company’s) assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s securities. This document
Slide 3: Double digit growth across all regions
Double digit growth across all regions New management commenced FY24 H2 +22% Revenue growth +10% • Delivered revenue of $111.5m vs guidance of $105m. • Revenue growth of +22% vs pcp. +15% • Double digit growth across all regions. Earnings growth • EBITDA1 of $9.2m (+$8.6m vs pcp), with $111 margin i
Slide 4: Building the foundations for profitable growth
Building the foundations for profitable growth Manufacturing Manufacturing capacity Capacity increased over 50% from peak of manufacturing growth constraints in FY24 H2 Customer Improved turnaround times Turn around times significantly improved and backlog now at negligible levels People & culture H
Slide 5: Rest Assure®
Rest Assure® • FDA cleared Rest Assure® as the first oral device with built-in compliance monitoring. • Clearance includes the oral device and software platform incl. patient app, physician platform, docking station and cloud systems. • US clinical study to commence in FY26 to support FDA 510k submi
Slide 6: Strategy and Outlook
Strategy and Outlook FY25 FY26 FY27 and beyond Execution and Sustainable Stabilisation and delivery – year of growth and innovation reset investment • Financial: >10+% EBITDA1 ✓ People and culture: build a high • Financial: sustainable revenue margins performing team and culture of and margin growth
Slide 7: SomnoMed's Opportunity
SomnoMed's Opportunity VISION INVESTMENT HIGHLIGHTS A world where our oral appliance Significant total addressable market with 900+ million individuals therapy is the standard of care for sleep suffering from OSA globally. apnea treatment. Increasing consumer awareness, growth in GLP-1 drugs, and de
Slide 8: Reaffirming FY26 guidance
Reaffirming FY26 guidance Revenue EBITDA1 Capex2 $119m-$126m $10m-$12m $6m-$8m vs. $91.7m FY24 vs. $0.6m FY24 1 EBITDA excludes leases payments of between $3m-$3.5m, share/option expenses, unrealised foreign exchange gain/(loss), one-off costs and discontinued operations. 2 Capex spend expected to a
Slide 9: Thank You
Thank You © November 2025 SomnoMed 9
Slide 10: Chairman's AGM address by Guy Russo
27th November 2025 2025 Annual General Meeting Chairman’s AGM address by Guy Russo Dear Shareholders, On behalf of the Board of Directors, I am pleased to welcome you to the 2025 Annual General Meeting of SomnoMed Limited. It is a privilege to address you again and to reflect on a year that has mark
Slide 11: Co-CEOs' address by Karen Borg and Amrita Blickstead
Co-CEOs’ address by Karen Borg and Amrita Blickstead Amrita Blickstead: Thank you, Chairman, and good afternoon everyone. FY25 was a year defined by execution and transformation, when Karen and I stepped into these roles, our commitment was simple: rebuild trust, restore performance, and deliver on
Slide 12: Karen Borg: Thank you, Amrita
Karen Borg: Thank you, Amrita. A major highlight for us this year has been the progress on Rest Assure®. FY25 marked the FDA clearance of the compliance monitoring system, a global first. And FY26 is already seeing the next phase come to life. We’ve now secured our first US clinical site, the Clayto